Sorin develops and manufactures medical technologies and therapies for cardiac surgery and for the treatment of cardiac rhythm disorders. At the end of 2008, the company completed a programme of strategic divestitures and concluded a plan to restructure its business portfolio. The divestitures included the sale of its endovascular, coronary stent and renal care businesses. This has allowed the company to better focus on its three core businesses – Cardiac Rhythm Management (CRM), Cardiopulmonary and Heart Valves.
* The CRM business produces pacemakers, implantable cardioverter defibrillators (ICDs), cardiac resynchronisation therapy defibrillators (CRT-Ds), programmers, electrodes, electrophysiology leads and holter monitors.
* The Cardiopulmonary business produces extracorporeal blood circulation systems including oxygenators, heart-lung machines, perfusion tubing sets, autotransfusion systems and disposables, cannulae and endoscopic vessel harvesting (EVH) systems.
* The Heart Valves business offers mechanical heart valves, tissue heart valves, sutureless self-anchoring tissue valves and annuloplasty rings. Sorin is also a distributor of endovascular devices.
Sorin’s recent investments in developing its business include the purchase of equity stakes in Enopace Biomedical (a company developing a neuromodulation system to treat patients with congestive heart failure) and MD Start (a venture capital incubator), as well as the acquisition of a line of arterial and venous cannulae from Endoscopic Technologies Inc and the purchase of Gish Biomedical (a producer of disposable medical devices for cardiovascular surgery).
Sorin’s principal manufacturing and R&D facilities are located in Italy, France, Germany, Canada and the US. The company is present in more than 80 countries throughout the world and serves over 5,000 public and private health institutions.
The Sorin Group was created through the demerger of Snia’s biomedical operations. It was listed separately on the Online Stock Market of the Milan Securities Exchange in January 2004. As of January 2012, its main shareholders included: Bios SpA (19.1%); Tower 6Bis Sarl (6.7%); Banca Monte Dei Paschi di Siena SpA (7.3%); Unipol Assicurazioni SpA (4.6%); GE Capital Equity Holdings (6.4%); and Norges Bank (2.0%).
In 2011, Sorin generated net income of EUR58 million on sales of EUR743 million. The company employs more than 3,740 people worldwide.
This company report provides
Key contact information
Introduction to the company and its current activities
Summary of its financial performance
Who are the company’s major competitors?
Key recent events in an “at a glance” format
Current year and annual financial data, including revenue breakdowns by product area and geographic region (if available)
Table providing in-depth five-year financial analysis
Employee data, including breakdown by company division and geographic location
Investigates the company’s aims and its areas of focus
Core product areas, key brands, product approvals and launches
Research and Development
How much has been invested in R&D?
Where is the research based?
What alliances and agreements does the company have and with whom?
Manufacturing and Distribution
Identifying the company’s manufacturing locations
Sales and marketing facilities
With whom has the company reached agreements and what do they involve?
Key contracts awarded
Mergers, Acquisitions, Minority Investments, Joint Ventures and Divestments
Key Corporate Events
For more information kindly visit :
Sorin Medical Device Company Intelligence Report
Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Fax: + 91 22 27812290
Follow us on twitter: http://twitter.com/#!/Sandhya3B
Our Blogs: http://bharatbook.posterous.com/